Titre : ARN ribosomique 18S

ARN ribosomique 18S : Questions médicales fréquentes

Termes MeSH sélectionnés :

Electron Transport Complex IV
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "ARN ribosomique 18S : Questions médicales les plus fréquentes", "headline": "ARN ribosomique 18S : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les ARN ribosomique 18S : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-09", "dateModified": "2025-03-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "ARN ribosomique 18S" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "ARN ribosomique", "url": "https://questionsmedicales.fr/mesh/D012335", "about": { "@type": "MedicalCondition", "name": "ARN ribosomique", "code": { "@type": "MedicalCode", "code": "D012335", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.444.735.686" } } }, "about": { "@type": "MedicalCondition", "name": "ARN ribosomique 18S", "alternateName": "RNA, Ribosomal, 18S", "code": { "@type": "MedicalCode", "code": "D012337", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Harutaro Kenmotsu", "url": "https://questionsmedicales.fr/author/Harutaro%20Kenmotsu", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Yuu Hirose", "url": "https://questionsmedicales.fr/author/Yuu%20Hirose", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Toshihiko Eki", "url": "https://questionsmedicales.fr/author/Toshihiko%20Eki", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Ludivine Wacheul", "url": "https://questionsmedicales.fr/author/Ludivine%20Wacheul", "affiliation": { "@type": "Organization", "name": "RNA Molecular Biology, ULB Cancer Research Center (U-CRC), Centre for Microscopy and Molecular Imaging (CMMI), Fonds de la Recherche Scientifique (F.R.S.-FNRS), Université Libre de Bruxelles (ULB), Charleroi-Gosselies, Belgium." } }, { "@type": "Person", "name": "Anil Kumar Nehra", "url": "https://questionsmedicales.fr/author/Anil%20Kumar%20Nehra", "affiliation": { "@type": "Organization", "name": "Department of Veterinary Parasitology, Lala Lajpat Rai University of Veterinary and Animal Sciences, 125004, Hisar, Haryana, India. anilnehra15@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway.", "datePublished": "2024-01-29", "url": "https://questionsmedicales.fr/article/38290207", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.intimp.2024.111588" } }, { "@type": "ScholarlyArticle", "name": "Fe(IV)/Fe(V)-mediated polyferric sulfate/periodate system: A novel coagulant/oxidant strategy in promoting micropollutant abatement.", "datePublished": "2024-01-26", "url": "https://questionsmedicales.fr/article/38290329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jhazmat.2024.133614" } }, { "@type": "ScholarlyArticle", "name": "Neutrophil-mediated type IV collagen degradation is elevated in patients with mild endoscopic ulcerative colitis reflecting early mucosal destruction.", "datePublished": "2024-01-18", "url": "https://questionsmedicales.fr/article/38238446", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-52208-y" } }, { "@type": "ScholarlyArticle", "name": "Identification and management of low-risk isolated traumatic brain injury patients initially treated at a rural level IV trauma center.", "datePublished": "2024-01-12", "url": "https://questionsmedicales.fr/article/38266433", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajem.2024.01.014" } }, { "@type": "ScholarlyArticle", "name": "Robotic Hepatectomy plus Biliary Reconstruction for Bismuth Type III and Type IV Hilar Cholangiocarcinoma: State of the Art and Literature Review.", "datePublished": "2023-12-21", "url": "https://questionsmedicales.fr/article/38276227", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/jpm14010012" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides nucléiques, nucléotides et nucléosides", "item": "https://questionsmedicales.fr/mesh/D009706" }, { "@type": "ListItem", "position": 3, "name": "Acides nucléiques", "item": "https://questionsmedicales.fr/mesh/D009696" }, { "@type": "ListItem", "position": 4, "name": "ARN", "item": "https://questionsmedicales.fr/mesh/D012313" }, { "@type": "ListItem", "position": 5, "name": "ARN ribosomique", "item": "https://questionsmedicales.fr/mesh/D012335" }, { "@type": "ListItem", "position": 6, "name": "ARN ribosomique 18S", "item": "https://questionsmedicales.fr/mesh/D012337" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : ARN ribosomique 18S - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur ARN ribosomique 18S", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-04", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur ARN ribosomique 18S", "description": "Comment détecte-t-on l'ARN ribosomique 18S ?\nQuels tests sont utilisés pour l'analyse de l'ARN 18S ?\nL'ARN 18S est-il spécifique à certaines espèces ?\nPeut-on quantifier l'ARN 18S ?\nQuels échantillons sont nécessaires pour l'analyse de l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur ARN ribosomique 18S", "description": "Quels symptômes sont liés à des anomalies de l'ARN 18S ?\nL'ARN 18S affecte-t-il la santé cellulaire ?\nDes infections peuvent-elles influencer l'ARN 18S ?\nY a-t-il des signes de cancer liés à l'ARN 18S ?\nL'ARN 18S est-il impliqué dans des maladies neurodégénératives ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur ARN ribosomique 18S", "description": "Comment prévenir les anomalies de l'ARN 18S ?\nL'éducation génétique peut-elle aider à prévenir des maladies liées à l'ARN 18S ?\nDes dépistages réguliers sont-ils recommandés ?\nLes vaccinations influencent-elles l'ARN 18S ?\nY a-t-il des recommandations alimentaires pour la santé de l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur ARN ribosomique 18S", "description": "Quels traitements ciblent l'ARN 18S ?\nL'ARN 18S peut-il être utilisé en thérapie ?\nComment les antibiotiques affectent-ils l'ARN 18S ?\nY a-t-il des traitements pour les anomalies de l'ARN 18S ?\nLes thérapies ciblées peuvent-elles influencer l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur ARN ribosomique 18S", "description": "Quelles complications peuvent survenir avec des anomalies de l'ARN 18S ?\nL'ARN 18S est-il lié à des complications respiratoires ?\nDes complications neurologiques peuvent-elles être liées à l'ARN 18S ?\nL'ARN 18S peut-il être impliqué dans des complications cancéreuses ?\nQuelles sont les complications métaboliques liées à l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur ARN ribosomique 18S", "description": "Quels facteurs de risque sont associés à des anomalies de l'ARN 18S ?\nL'exposition à des toxines affecte-t-elle l'ARN 18S ?\nLe stress oxydatif influence-t-il l'ARN 18S ?\nDes habitudes alimentaires peuvent-elles influencer l'ARN 18S ?\nL'âge est-il un facteur de risque pour l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Electron+Transport+Complex+IV&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on l'ARN ribosomique 18S ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'ARN 18S est souvent détecté par PCR ou séquençage pour identifier des organismes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'analyse de l'ARN 18S ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'électrophorèse et l'hybridation pour évaluer la qualité de l'ARN." } }, { "@type": "Question", "name": "L'ARN 18S est-il spécifique à certaines espèces ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'ARN 18S présente des variations spécifiques aux espèces, utile pour l'identification." } }, { "@type": "Question", "name": "Peut-on quantifier l'ARN 18S ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la quantification se fait par RT-qPCR pour mesurer l'expression génique." } }, { "@type": "Question", "name": "Quels échantillons sont nécessaires pour l'analyse de l'ARN 18S ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des échantillons de tissus, cellules ou fluides biologiques sont requis pour l'analyse." } }, { "@type": "Question", "name": "Quels symptômes sont liés à des anomalies de l'ARN 18S ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent entraîner des troubles de croissance ou des maladies génétiques." } }, { "@type": "Question", "name": "L'ARN 18S affecte-t-il la santé cellulaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'ARN 18S peuvent perturber la synthèse protéique et la santé cellulaire." } }, { "@type": "Question", "name": "Des infections peuvent-elles influencer l'ARN 18S ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent altérer l'expression de l'ARN 18S, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des signes de cancer liés à l'ARN 18S ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux d'ARN 18S modifiés peuvent être associés à certains types de cancer." } }, { "@type": "Question", "name": "L'ARN 18S est-il impliqué dans des maladies neurodégénératives ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'ARN 18S et certaines maladies neurodégénératives." } }, { "@type": "Question", "name": "Comment prévenir les anomalies de l'ARN 18S ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne nutrition et un mode de vie sain peuvent aider à prévenir les anomalies génétiques." } }, { "@type": "Question", "name": "L'éducation génétique peut-elle aider à prévenir des maladies liées à l'ARN 18S ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation génétique permet de mieux comprendre les risques et de prendre des mesures préventives." } }, { "@type": "Question", "name": "Des dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages réguliers peuvent aider à identifier précocement des anomalies génétiques." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles l'ARN 18S ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations peuvent indirectement influencer l'expression de l'ARN 18S en renforçant l'immunité." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires pour la santé de l'ARN 18S ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en acides gras oméga-3 et en antioxydants peut soutenir la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements ciblent l'ARN 18S ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments peuvent cibler l'expression de l'ARN 18S." } }, { "@type": "Question", "name": "L'ARN 18S peut-il être utilisé en thérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches thérapeutiques exploitent l'ARN 18S pour traiter certaines maladies." } }, { "@type": "Question", "name": "Comment les antibiotiques affectent-ils l'ARN 18S ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains antibiotiques ciblent les ribosomes, affectant ainsi l'ARN 18S et la synthèse protéique." } }, { "@type": "Question", "name": "Y a-t-il des traitements pour les anomalies de l'ARN 18S ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements spécifiques peuvent être développés pour corriger les anomalies de l'ARN 18S." } }, { "@type": "Question", "name": "Les thérapies ciblées peuvent-elles influencer l'ARN 18S ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les thérapies ciblées peuvent moduler l'expression de l'ARN 18S dans certaines pathologies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies de l'ARN 18S ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles métaboliques et des maladies héréditaires." } }, { "@type": "Question", "name": "L'ARN 18S est-il lié à des complications respiratoires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent un lien potentiel entre l'ARN 18S et certaines infections respiratoires." } }, { "@type": "Question", "name": "Des complications neurologiques peuvent-elles être liées à l'ARN 18S ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de l'ARN 18S peuvent être associées à des troubles neurologiques." } }, { "@type": "Question", "name": "L'ARN 18S peut-il être impliqué dans des complications cancéreuses ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux d'ARN 18S sont souvent observés dans divers types de cancers." } }, { "@type": "Question", "name": "Quelles sont les complications métaboliques liées à l'ARN 18S ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de l'ARN 18S peuvent entraîner des déséquilibres métaboliques et des syndromes." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à des anomalies de l'ARN 18S ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs génétiques, environnementaux et nutritionnels peuvent influencer l'ARN 18S." } }, { "@type": "Question", "name": "L'exposition à des toxines affecte-t-elle l'ARN 18S ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut altérer l'expression de l'ARN 18S et causer des dommages." } }, { "@type": "Question", "name": "Le stress oxydatif influence-t-il l'ARN 18S ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut affecter la stabilité et l'expression de l'ARN 18S." } }, { "@type": "Question", "name": "Des habitudes alimentaires peuvent-elles influencer l'ARN 18S ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut affecter l'expression de l'ARN 18S et la santé cellulaire." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour l'ARN 18S ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut entraîner des modifications de l'expression de l'ARN 18S." } } ] } ] }

Sources (10000 au total)

Astragaloside IV alleviates macrophage senescence and d-galactose-induced bone loss in mice through STING/NF-κB pathway.

Senile osteoporosis (SOP) is an age-related metabolic bone disease that currently lacks specific therapeutic interventions. Thus, this study aimed to investigate the effect of Astragaloside IV (AS-IV)... A senescent macrophage model was established and treated with varying concentrations of AS-IV. Cell activity was measured using the CCK8 assay. The senescence levels of macrophages were evaluated thro... AS-IV inhibited macrophage senescence and M1 polarization, alleviated mitochondrial dysfunction, and promoted M2 polarization. Mechanistically, it suppressed the STING/NF-κB pathway in H2O2-activated ... By modulating the STING/NF-κB signaling pathway, AS-IV potentially inhibited macrophage senescence and stimulated osteogenic differentiation of BMSCs, thus exerting an anti-osteoporotic effect. Conseq...

Identification and management of low-risk isolated traumatic brain injury patients initially treated at a rural level IV trauma center.

Our goal was to determine if low-risk, isolated mild traumatic brain injury (TBI) patients who were initially treated at a rural emergency department may have been safely managed without transfer to t... This was a retrospective observational analysis of isolated mild TBI patients who were transferred from a rural Level IV Trauma Center to a regional Level I Trauma Center between 2018 and 2022. Patien... 250 patients with isolated mild TBI were transferred out to the Level I Trauma Center. Fall was the most common mechanism of injury (69.2%). 28 patients (11.2%) were categorized as low-risk (mBIG1). N... We propose that patients who meet mBIG1 criteria may be safely observed without transfer to a referral Level I Trauma Center. This would be of considerable benefit to patients, who would not need to l...

Robotic Hepatectomy plus Biliary Reconstruction for Bismuth Type III and Type IV Hilar Cholangiocarcinoma: State of the Art and Literature Review.

In Bismuth type III and IV Hilar Cholangiocarcinoma (III-IV HC), surgical resection is the only chance for long-term survival. As the surgical procedure is complex and Robotic-Assisted Surgery (RAS) m... We conducted a systematic review using the PRISMA checklist for article selection. We searched the PubMed database and included only studies with clinical data about the treatment of III-IV HC using R... A total of 12 papers involving 50 patients were included. All cases were Bismuth IIIa (... RAS for III-IV HC is safe and feasible, at least if performed by experienced surgeons on selected cases. The oncological outcomes appear acceptable, given the aggressiveness of this pathology, but fur...

Low body temperature and mortality in critically ill patients with coronary heart disease: a retrospective analysis from MIMIC-IV database.

This study was aimed to investigate the correlation between low body temperature and outcomes in critically ill patients with coronary heart disease (CHD).... Participants from the Medical Information Mart for Intensive Care (MIMIC)-IV were divided into three groups (≤ 36.5 ℃, 36.6-37.4 ℃, ≥ 37.5 ℃) in accordance with body temperature measured orally in ICU... A total of 8577 patients (65% men) were included. The in-hospital, 28-day, 90-day, and 1-year overall mortality rate were 10.9%, 16.7%, 21.5%, and 30.4%, respectively. Multivariable Cox proportional h... Low body temperature was associated with increased mortality in critically ill patients with coronary heart disease....

Characteristics, Treatment Patterns and Survival of International Federation of Gynecology and Obstetrics Stage IV Epithelial Ovarian Cancer-A Population-Based Study.

The aim of the present study was to describe an unselected population of patients with diagnosis of FIGO stage IV OC.... Data from 1183 patients were available for analysis.... The majority of patients (962/1183, 81.3%) received cancer-directed treatment. The median follow-up time was 3.8 years, and the median overall survival duration was 1.9 years. Notably, patients >80 ye... In this cohort of patients with FIGO stage IV OC, more than 80% of the patients received cancer-directed treatment. Age and high-grade serous histology were determinants for survival. The highest over...